212 related articles for article (PubMed ID: 23598719)
1. Caveolin-1 is a negative regulator of tumor growth in glioblastoma and modulates chemosensitivity to temozolomide.
Quann K; Gonzales DM; Mercier I; Wang C; Sotgia F; Pestell RG; Lisanti MP; Jasmin JF
Cell Cycle; 2013 May; 12(10):1510-20. PubMed ID: 23598719
[TBL] [Abstract][Full Text] [Related]
2. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
[TBL] [Abstract][Full Text] [Related]
3. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
4. Xihuang pill potentiates the anti-tumor effects of temozolomide in glioblastoma xenografts through the Akt/mTOR-dependent pathway.
Fu J; Zhu SH; Xu HB; Xu YQ; Wang X; Wang J; Kong PS
J Ethnopharmacol; 2020 Oct; 261():113071. PubMed ID: 32603676
[TBL] [Abstract][Full Text] [Related]
5. miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.
Li S; Zeng A; Hu Q; Yan W; Liu Y; You Y
Neuro Oncol; 2017 Jan; 19(1):55-65. PubMed ID: 27471108
[TBL] [Abstract][Full Text] [Related]
6. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
7. Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway.
Miao L; Jiang Z; Wang J; Yang N; Qi Q; Zhou W; Feng Z; Li W; Zhang Q; Huang B; Chen A; Zhang D; Zhao P; Li X
Oncol Rep; 2019 Aug; 42(2):605-614. PubMed ID: 31233190
[TBL] [Abstract][Full Text] [Related]
8. Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?
Daisy Precilla S; Biswas I; Kuduvalli SS; Anitha TS
Cell Signal; 2022 Jul; 95():110350. PubMed ID: 35525406
[TBL] [Abstract][Full Text] [Related]
9. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.
Prasad G; Sottero T; Yang X; Mueller S; James CD; Weiss WA; Polley MY; Ozawa T; Berger MS; Aftab DT; Prados MD; Haas-Kogan DA
Neuro Oncol; 2011 Apr; 13(4):384-92. PubMed ID: 21317208
[TBL] [Abstract][Full Text] [Related]
11. Mechanosensitive caveolin-1 activation-induced PI3K/Akt/mTOR signaling pathway promotes breast cancer motility, invadopodia formation and metastasis in vivo.
Yang H; Guan L; Li S; Jiang Y; Xiong N; Li L; Wu C; Zeng H; Liu Y
Oncotarget; 2016 Mar; 7(13):16227-47. PubMed ID: 26919102
[TBL] [Abstract][Full Text] [Related]
12. MiR-223/PAX6 Axis Regulates Glioblastoma Stem Cell Proliferation and the Chemo Resistance to TMZ via Regulating PI3K/Akt Pathway.
Huang BS; Luo QZ; Han Y; Huang D; Tang QP; Wu LX
J Cell Biochem; 2017 Oct; 118(10):3452-3461. PubMed ID: 28332226
[TBL] [Abstract][Full Text] [Related]
13. MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival.
Radoul M; Chaumeil MM; Eriksson P; Wang AS; Phillips JJ; Ronen SM
Mol Cancer Ther; 2016 May; 15(5):1113-22. PubMed ID: 26883274
[TBL] [Abstract][Full Text] [Related]
14. Combination treatment of berberine and solid lipid curcumin particles increased cell death and inhibited PI3K/Akt/mTOR pathway of human cultured glioblastoma cells more effectively than did individual treatments.
Maiti P; Plemmons A; Dunbar GL
PLoS One; 2019; 14(12):e0225660. PubMed ID: 31841506
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of Src enhances the cytotoxic effect of temozolomide through AKT in glioma.
Wang Z; Sun J; Li X; Yang S; Yue S; Zhang J; Yang X; Zhu T; Jiang R; Yang W
Oncol Rep; 2013 Apr; 29(4):1395-8. PubMed ID: 23338526
[TBL] [Abstract][Full Text] [Related]
16. Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition.
Zhang WB; Wang Z; Shu F; Jin YH; Liu HY; Wang QJ; Yang Y
J Biol Chem; 2010 Dec; 285(52):40461-71. PubMed ID: 20880848
[TBL] [Abstract][Full Text] [Related]
17. A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
Ströbele S; Schneider M; Schneele L; Siegelin MD; Nonnenmacher L; Zhou S; Karpel-Massler G; Westhoff MA; Halatsch ME; Debatin KM
PLoS One; 2015; 10(6):e0131670. PubMed ID: 26121251
[TBL] [Abstract][Full Text] [Related]
18. The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death.
Chen PH; Cheng CH; Shih CM; Ho KH; Lin CW; Lee CC; Liu AJ; Chang CK; Chen KC
PLoS One; 2016; 11(11):e0167096. PubMed ID: 27893811
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide.
Sinnberg T; Lasithiotakis K; Niessner H; Schittek B; Flaherty KT; Kulms D; Maczey E; Campos M; Gogel J; Garbe C; Meier F
J Invest Dermatol; 2009 Jun; 129(6):1500-15. PubMed ID: 19078992
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of MDR1 by Ad-DKK3 via Akt/NFκB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model.
Fujihara T; Mizobuchi Y; Nakajima K; Kageji T; Matsuzaki K; Kitazato KT; Otsuka R; Hara K; Mure H; Okazaki T; Kuwayama K; Nagahiro S; Takagi Y
J Neurooncol; 2018 Sep; 139(2):323-332. PubMed ID: 29779087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
